Color Stability Assessment of Light and Self-Cured Composites Following Accelerated Aging

Svrha istraživanja bila je izmjeriti i usporediti unutarnju stabilnost boje triju svjetlosnopolimerizirajućih materijala i jednoga kemijski stvrdnjavajućeg nakon njihova ubrzanog starenja. Materijali i metode: Testovi za stabilnost boja obavljeni su na svjetlosnopolimerizirajućim kompozitima – nanopunjenju Filtek Supreme XT (3M ESPE), nanohibridu Tetric Evo Ceram (Ivoclar Vivadent) i mikrohibridu Herculite XRV (Kerr) te na samopolimerizirajućem kompozitu Bisfil II (Bisco). Svi uzorci bili su uronjeni u destiliranu vodu (37°C) i držani u tamnoj posudi 24 sata. Nakon toga podijeljeni su u tri skupine. Postupak ubrzanog starenja proveden je prema dvama protokolima – u vodenoj kupelji na 60°C i prema ISO-u 7491. Uzorci iz kontrolne skupine držani su u destiliranoj vodi 30 dana na temperaturi od 37°C. Razlike u boji – ΔE, računale su se iz koordinata CIE L*a*b* izmjerenih spektrofotometrom nasuprot bijeloj pozadini prije postupka starenja uzoraka i poslije njega. Razina osjetljivosti boje postavljena je na 1, a prihvatljivi šum na 3,5. Statistička analiza obavljena je uparenim t-testom i ANOVA-om (p≤0,05). Rezultati: Svi ispitani materijali pokazali su klinički neprihvatljive promjene boje nakon ubrzanog starenja u vodenoj kupelji, a fotostarenjem nastala je vidljiva promjena boje kod svih svjetlosnopolimerizirajućih kompozita. Nanokompozitni materijali značajno su promijenili boju i u kontrolnoj skupini. Zaključak: Unutarnja stabilnost boje testiranih materijala ovisi o uvjetima starenja i vrsti dentalnog kompozita. Kemijski stvrdnjavajući kompoziti pokazali su tijekom fotostarenja bolju stabilnost.Objectives: Measure and compare internal color stability of three light-cured composites and one chemically bonded material after their accelerated aging. Materials and Methods: Color stability tests included nano-filled Filtek Supreme XT (3M ESPE), nano-hybrid Tetric Evo Ceram (Ivoclar Vivadent), microhybrid Herculite XRV (Kerr) of light cured and Bisfil II (Bisco) of self cured composites. All samples were immersed in distilled water of 37°C and kept in a dark chamber during 24 hours. Thereafter they were divided into three groups. Accelerated aging was performed in accordance with the two different protocols, i.e. water bath at 60°C and ISO 7491. Control group specimens were stored in distilled water at 37°C for 30 days. Color differences, ΔE were calculated from CIE L*a*b* coordinates measured with spectrophotometer against white backing before and after aging of samples. The color perceptibility threshold was set at 1.7 and acceptability threshold at 3.5. Statistical tests carried out on the groups included paired t-test and ANOVA (p≤0.05). Results: All tested materials showed clinically unacceptable color changes after accelerated aging in water bath, whereas photoaging induced perceptible color change in all light-cured composites. Nano-engineered composites significantly changed their color also in the control group. Conclusions: Internal color stability of tested materials depends on aging conditions and type of dental composite. Chemically-cured material showed better color stability by photo aging

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina.

The HERe2cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist